Tests proton radiation therapy for a rare chest lining cancer
Tests proton radiation on the chest in adults with pleural mesothelioma.
Plain-language title generated from the registry record
Registry title: Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
Key facts
- Where
- Barrow in Furness, Bodelwyddan, Bristol, Cambridge, Cardiff, Chelmsford, Eastbourne, Hull, Kings Lynn, Lancaster, Leeds, Leicester, Liverpool, London, Maidstone, Manchester, Newcastle upon Tyne, Portsmouth, Reading, Saint Leonards-on-Sea, Sheffield, Southend, and Torquay, United KingdomSee the 25 sites
Where in United Kingdom
- Furness General HospitalBarrow in Furness, United KingdomTaking people
- Betsi Cadwaladr University Health Board - Glan Clwyd HospitalBodelwyddan, United KingdomTaking people
- Southmead HospitalBristol, United KingdomTaking people
- Addenbrooke's HospitalCambridge, United KingdomTaking people
- Velindre Cancer CentreCardiff, United KingdomTaking people
- Broomfield HospitalChelmsford, United KingdomTaking people
- East Sussex Healthcare NHS Trust - Eastbourne HospitalEastbourne, United KingdomTaking people
- Queens Centre, Castle Hill HospitalHull, United KingdomTaking people
- Queen Elizabeth Hospital, King's LynnKings Lynn, United KingdomTaking people
- Royal Lancaster HospitalLancaster, United KingdomTaking people
- St James University HospitalLeeds, United KingdomTaking people
- Leicester Royal InfirmaryLeicester, United KingdomTaking people
- Clatterbridge Cancer CentreLiverpool, United KingdomTaking people
- St. Bartholomew's HospitalLondon, United KingdomTaking people
- University College London HospitalLondon, United KingdomTaking people
- Maidstone HospitalMaidstone, United KingdomTaking people
- Wythenshawe HospitalManchester, United KingdomTaking people
- Christie HospitalManchester, United KingdomNo longer taking part
- Freeman HospitalNewcastle upon Tyne, United KingdomTaking people
- Queen Alexandra HospitalPortsmouth, United KingdomTaking people
- Royal Berkshire HospitalReading, United KingdomTaking people
- East Sussex Healthcare NHS Trust - Conquest HospitalSaint Leonards-on-Sea, United KingdomTaking people
- Weston Park Cancer CentreSheffield, United KingdomTaking people
- Southend University HospitalSouthend, United KingdomTaking people
- Torbay HospitalTorquay, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University College, London
- Trial code
- NCT05655078
- Record updated
- 30 March 2026
- Original description
Phase III randomised-controlled trial for patients with unilateral malignant pleural mesothelioma (MPM).Read full original descriptionShow less
Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
Phase III randomised-controlled trial for patients with unilateral malignant pleural mesothelioma (MPM).
Inclusion: Patients ≥18 years of age, with biopsy confirmed MPM and histological subtyping (epithelioid or non-epithelioid); N0 or N1 and M0 disease; Written informed consent; Patient and local/regional MDT opt for active surveillance and deferral of SACT until clinical or radiological progression; WHO Performance Status 0-1; Disease confined to one hemithorax based on CT assessment; Adequate pulmonary function; ≥ 40% predicted post-FEV1; ≥ 40% predicted DLCO/TLCO; Agreement to travel to either proton beam therapy centres (i.e. UCLH or The Christie) if randomised to arm 2; Agreement to be followed up at a local HIT-Meso trial site; Patient likely able to complete PBT planning based on local assessment.
Exclusion: Prior thoracic radiotherapy, chemotherapy, immunotherapy for MPM; Prior radical surgery for MPM (extrapleural pneumonectomy or extended pleurectomy decortication or pleurectomy decortication); Initial systemic therapy or surgery is required and the patient and local/regional MDT do not opt for active surveillance; Patient with prior thoracic / abdominal radiotherapy for malignancy who was not discussed with sponsor before recruitment; Presence of metastatic or contralateral disease; T4 disease with invasion of the myocardium; N2 and/or M1 disease; Current or previous malignant disease which may impact on the patient's life expectancy; Diagnosis of clinically significant interstitial lung disease (ILD), excluding mild fibrosis or incidental findings; Chronic non-malignant disease with an estimated three-year survival rate of less than 20%; Cytological diagnosis and/or undetermined histological subtype; Involvement of contralateral or supraclavicular lymph nodes; Presence of new effusion that is not amenable to drainage; WHO Performance Status ≥ 2; Women who are pregnant or breast feeding; Patient fitted with a pacemaker or implantable cardioverter-defibrillator (ICD)\.